Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy
- Design
- Narrative review · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Population unclearUNKNOWN: a review whose underlying study populations are not described in the abstract.
- Could weight loss explain it?
- PossiblyThe abstract reports a harm association but no weight, glycaemic or mediation analysis; diabetes, hypertension, sleep apnoea and kidney disease are discussed as NAION risk factors, and the abstract does not say how they were separated from drug use.
- Study tier
- Not ratedNOT_RATED: review of published clinical, epidemiologic and pharmacovigilance data with no new primary data.
- Assessment
- Version 3 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This review of published studies looked at whether GLP-1 receptor agonists are linked to NAION, a sudden, painless and irreversible form of vision loss. Across health records, national registries and pharmacovigilance data, GLP-1RA use was associated with NAION, with relative risk estimates between 1.2 and 4.3, while the absolute incidence was very low. The authors treat this as a safety signal rather than a reason not to prescribe; the underlying data are observational, so this is an association, not proof that the drugs cause NAION.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists
- Dose
- various
- Comparator
- not reported in abstract
- Primary outcome
- risk of nonarteritic anterior ischemic optic neuropathy (NAION) with GLP-1RA use
- Effect
- Statistically significant association between GLP-1RA use and NAION, with relative risk estimates between 1.2 and 4.3 across health records, registries and pharmacovigilance analyses; very low absolute incidence
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- GLP-1RA use is associated with NAION (relative risk estimates between 1.2 and 4.3) with very low absolute incidence; the authors treat it as a safety signal, not a contraindication.
- Limitations
- Review of a structured PubMed search, not described as systematic and with no pooled analysis; the underlying data are observational, registry and pharmacovigilance sources, and NAION risk factors such as diabetes and sleep apnoea overlap with reasons for GLP-1RA use.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- not reported in abstract
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- not reported in abstract
Study quality details
- Study design
- Narrative review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- hard
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- UNKNOWN
- Statistical precision
- no CI reported; range of relative risk estimates only
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
Emerging data has identified a potential association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and nonarteritic anterior ischemic optic neuropathy (NAION), a typically sudden, painless, and irreversible cause of optic nerve-mediated vision loss. This review synthesizes the current clinical, epidemiologic, and potential mechanism linking GLP-1RA-based therapies to NAION risk, informing balanced risk assessment and interdisciplinary clinical decision-making. A structured PubMed search was performed using terms including "GLP-1 receptor agonist," "semaglutide," "liraglutide," "tirzepatide," and "nonarteritic anterior ischemic optic neuropathy," in addition to NAION risk factors, including disc-at-risk anatomy, type 2 diabetes, obstructive sleep apnea, hypertension, hyperlipidemia, renal disease, and ischemic heart disease. A small cup-to-disc ratio ("disc-at-risk") was found to be the most robust anatomical predictor of NAION. Systemic microvascular disease (diabetes, hypertension, hyperlipidemia) and conditions such as obstructive sleep apnea and end-stage renal disease were also linked to increased susceptibility to optic nerve head ischemia. Although data across electronic health records, national registries, and pharmacovigilance analyses suggest a very low absolute incidence of NAION, the use of GLP-1RAs demonstrates a statistically significant association with NAION development, yielding relative risk estimates between 1.2 and 4.3. At this time, the potential association between GLP-1RA therapy and NAION should be interpreted as a safety signal rather than a contraindication. Screening for disc-at-risk anatomy, consideration of prior NAION history, and patient counseling regarding acute visual symptoms may be warranted prior to initiation of therapy. As evidence evolves, collaboration between endocrinologists and ophthalmologists will be essential to support safe and effective patient care.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Oct 11, 2026 | 42857401 first ingestion |
| pubmed | Oct 11, 2026 | 42857401 duplicate matched on doi |
| pubmed | Oct 11, 2026 | 42857401 duplicate matched on doi |
| pubmed | Oct 18, 2026 | 42857401 duplicate matched on doi |
| pubmed | Oct 18, 2026 | 42857401 duplicate matched on doi |
| pubmed | Oct 18, 2026 | 42857401 duplicate matched on doi |